Glenmark

More documents

Recommendations

Info

Term Description Promoters The Promoters of the Company, being Saldanha Family Trust, Gracias Saldanha, B.E. Saldanha, Glenn Saldanha, Robin Pinto, Cheryl Pinto and Neha Saldanha QIBs or Qualified Qualified Institutional Buyers as defined under Regulation 2 (zd) of the Institutional Buyers SEBI Regulations QIP Qualified Institutions Placement under chapter VIII of the SEBI Regulations RBI The Reserve Bank of India Registered Office The registered office of the Company being B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 Regulation S Regulation S under the Securities Act RoC Registrar of Companies, Mumbai Rs./Rupees/INR Rupees, being the lawful currency for the time being of India SEBI The Securities and Exchange Board of India constituted under the SEBI Act SEBI Act The Securities and Exchange Board of India Act, 1992, as amended from time to time SEBI Regulations SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended from time to time Securities Act The US Securities Act of 1933 SICA Sick Industrial Companies (Special Provisions) Act, 1995 Stock Exchanges/ Indian NSE and BSE Stock Exchanges Takeover Code The SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997, as amended from time to time United States/ USA The United States of America US GAAP Generally accepted accounting principles in the Unites States of America US$/ USD/ US Dollars US dollars, the lawful currency for the time being of the Unites States of America GENERAL INDUSTRY TERMS Term Description ANDAs Abbreviated New Drug Applications API Active Pharmaceutical Ingredients CAGR Compound annual growth rate CDSCO Central Drugs Standard Control Organisation CGMP Current Good Manufacturing Practice CIS Commonwealth of Independent States CRAMS Contract research and manufacturing services DCA Drugs and Cosmetics Act, 1940 DCGI Drug Controller General of India DMF Drug Master Files DPCO Drug (Prices Control) Order, 1995 DTAB Drug Technical Advisory Board EMRs Exclusive Marketing Rights GATT General Agreement on Tariffs and Trade HMO Health maintenance organisations ICH International Conference on Harmonisation ICMR Indian Council of Medical Research IDA International Dispensary Association IEC Institutional ethics committee IMS IMS Health Incorporated MHRA Medicines and Healthcare Products Regulatory Agency, U.K MNC Multinational Corporation v
Term NBE NCE NDDS NPPA OTC PCB TRIPS USFDA WHO WTO Description New biological entity New chemical entity New Drug Delivery System National Pharmaceutical Pricing Authority Over the counter Pollution Control Board Trade-Related Aspects of Intellectual Property Rights United States Food and Drug Administration World Health Organisation World Trade Organisation vi
Page 1 and 2: Preliminary Placement Document Not
Page 3 and 4: NOTICE TO INVESTORS The Company acc
Page 5 and 6: the Issue and are in no way acting
Page 7 and 8: liable for your decision to partici
Page 9 and 10: ENFORCEMENT OF CIVIL LIABILITIES Th
Page 11 and 12: FORWARD LOOKING STATEMENTS All stat
Page 13: Term Description Director(s) Direct
Page 17 and 18: Use of Proceeds Lock-up Risk Factor
Page 19 and 20: jurisdictions including Thailand, E
Page 21 and 22: with commercialisation of Eszopiclo
Page 23 and 24: of the patent and Paragraph IV fili
Page 25 and 26: As at March 31, 2007 As at March 31
Page 27 and 28: If our research and development eff
Page 29 and 30: consumer acceptance, we may be requ
Page 31 and 32: Our performance is highly dependent
Page 33 and 34: portfolio of products that are prom
Page 35 and 36: esults. Historically, in addition t
Page 37 and 38: equirements for the above raw mater
Page 39 and 40: and approvals may result in their e
Page 41 and 42: plants to our customers located glo
Page 43 and 44: dividends is subject to the discret
Page 45 and 46: It may not be possible for you to e
Page 47 and 48: In addition, the Indian stock marke
Page 49 and 50: MARKET PRICE INFORMATION The Compan
Page 51 and 52: (in Rs. million) Period BSE NSE Mar
Page 53 and 54: The following table shows, as at Ma
Page 55 and 56: Under current Indian tax laws, divi
Page 57 and 58: Our Specialty Business is operated
Page 59 and 60: · devaluation of currencies in key
Page 61 and 62: Balance Sheet date there is an indi
Page 63 and 64: Results of Operations The following
Page 65 and 66:
Other Income The total income from
Page 67 and 68:
Provision for Taxation Our provisio
Page 69 and 70:
investments. The Group has financed
Page 71 and 72:
Related Party Transactions The Grou
Page 73 and 74:
Foreign Currency Exchange Rate Risk
Page 75 and 76:
World Pharmaceutical Market 2008 Sh
Page 77 and 78:
examined to determine whether any o
Page 79 and 80:
Further, there are promising opport
Page 81 and 82:
as patents expire and the shifting
Page 83 and 84:
jurisdictions including Thailand, E
Page 85 and 86:
with commercialisation of Eszopiclo
Page 87 and 88:
of the patent and Paragraph IV fili
Page 89 and 90:
Our India branded generics business
Page 91 and 92:
Asia Pacific region, we have filed
Page 93 and 94:
pursuant to the collaboration. Purs
Page 95 and 96:
North America / United States Formu
Page 97 and 98:
other APIs include products ranging
Page 99 and 100:
iological matrix. These validated a
Page 101 and 102:
Properties Our properties are used
Page 103 and 104:
Entity Jurisdiction Shareholding Ac
Page 105 and 106:
procedures involve obtaining a seri
Page 107 and 108:
Name, DIN, Designation, Term and Ad
Page 109 and 110:
Name, DIN, Designation, Term and Ad
Page 111 and 112:
degrees from Royal Institute of Pub
Page 113 and 114:
shall not be paid remuneration exce
Page 115 and 116:
Achin Gupta, 33, is the vice presid
Page 117 and 118:
Compensation Committee The Compensa
Page 119 and 120:
PRINCIPAL SHAREHOLDERS The Company
Page 121 and 122:
S. No Name of the Shareholder No. o
Page 123 and 124:
Issue Procedure 1. The Company and
Page 125 and 126:
No Allotment shall be made pursuant
Page 127 and 128:
Name: Citigroup Global Markets Indi
Page 129 and 130:
2. In accordance with the SEBI Regu
Page 131 and 132:
PLACEMENT Memorandum of Understandi
Page 133 and 134:
SELLING RESTRICTIONS The distributi
Page 135 and 136:
a) made by an investment firm, bank
Page 137 and 138:
TRANSFER RESTRICTIONS Allottees are
Page 139 and 140:
The exceptions to this rule are for
Page 141 and 142:
company is subject to continuing di
Page 143 and 144:
case may be. Such company in turn i
Page 145 and 146:
entering into an agreement for the
Page 147 and 148:
two depositories that provide elect
Page 149 and 150:
the shareholders entitled to the pa
Page 151 and 152:
available for dividends or out of t
Page 153 and 154:
Annual Report and Financial Results
Page 155 and 156:
shareholder or repayment of any ter
Page 157 and 158:
6. Under section 35 of the Income T
Page 159 and 160:
7. Under section 111A of the Income
Page 161 and 162:
1. In terms of section 10(34) of th
Page 163 and 164:
LEGAL PROCEEDINGS Except as disclos
Page 165 and 166:
dated April 21, 2004, and the Compa
Page 167 and 168:
2002 in 2048/S/98) dated September
Page 169 and 170:
6. The Assessing Officer had held t
Page 171 and 172:
making payment within requisite tim
Page 173 and 174:
FINANCIAL STATEMENTS GLENMARK PHARM
Page 175 and 176:
For and on behalf of the Board of D
Page 177 and 178:
This is the Consolidated Profit and
Page 179 and 180:
Year ended 31st March,2009 Year end
Page 181 and 182:
As at 31st March,2009 As at 31st Ma
Page 183 and 184:
100 each fully paid up of Marksans
Page 185 and 186:
14. PROVISIONS As at 31st March,200
Page 187 and 188:
As on 31st March, 2008 Acquisition
Page 189 and 190:
Page 191 and 192:
GLENMARK PHARMACEUTICALS LIMITED SC
Page 193 and 194:
(a) (b) (c) (d) In respect of Subsi
Page 195 and 196:
ix) Revenue Recognition The Group r
Page 197 and 198:
For basic earnings per share 250,02
Page 199 and 200:
In accordance with the requirements
Page 201 and 202:
(i) (ii) (iii) Change in Defined Be
Page 203 and 204:
The Company has opted to follow the
Page 205 and 206:
GLENMARK PHARMACEUTICALS LIMITED AU
Page 207 and 208:
This is the Consolidated Balance Sh
Page 209 and 210:
Partha Ghosh Glenn Saldanha Rajesh
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
(i) (ii) (iii) Convertible at the o
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
2) SIGNIFICANT ACCOUNTING POLICIES
Page 227 and 228:
v) Foreign Currency Transactions (a
Page 229 and 230:
4) CONTINGENT LIABILITIES NOT PROVI
Page 231 and 232:
a) Key management personnel Mr. Gra
Page 233 and 234:
Rs. In ('000s) 31st Mar, 2008 31st
Page 235 and 236:
GLENMARK PHARMACEUTICALS LIMITED Au
Page 237 and 238:
Schedules referred to above and not
Page 239 and 240:
Schedules referred to above and not
Page 241 and 242:
Page 243 and 244:
2. RESERVES AND SURPLUS Note As at
Page 245 and 246:
B) The Company had issued 20,000 Ze
Page 247 and 248:
As at 31st March,2007 Rs. In ('000s
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Revenues and expenses are translate
Page 257 and 258:
consumed, labour and manufacturing
Page 259 and 260:
3) CONTINGENT LIABILITIES NOT PROVI
Page 261 and 262:
6) RELATED PARTY DISCLOSURES a) Rel
Page 263 and 264:
(ii) The lease income of Rs.Nil (20
Page 265 and 266:
7. Glenmark Pharmaceuticals limited
Page 267 and 268:
ii) To the Foreign Currency Monetar
Page 269:
ISSUER GLENMARK PHARMACEUTICALS LIM
show all

Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?